Most of the 400 million grass pollen-allergic patients worldwide are co-sensitized to several unrelated grass pollen allergens. Based on frequent co-sensitization patterns determined in 200 grass pollen-allergic patients, three recombinant hybrid molecules were developed by polymerase chain reaction-based mending of cDNAs coding for the major timothy grass pollen allergens (Phl p 1, Phl p 2, Phl p 5, Phl p 6) for vaccination against grass pollen allergy. The hybrids rP2-P6, rP6-P2, and rP5-P1 contained most of the epitopes of natural grass pollen extract and induced stronger lymphoproliferative responses in cultured mononuclear cells of grass pollen-allergic patients than did equimolar mixtures of the individual allergens. Immunization of mice with the hybrids yielded higher antibody titers than did immunization with the individual allergen components or grass pollen extract, which suggests that the individual components of the hybrids can serve as molecular scaffolds for each other to enhance their immunogenicity. Antibodies induced with the hybrids in mice inhibited the binding of grass pollen-allergic patients' immunoglobulin E to each of the individual allergens and grass pollen extract and may thus represent protective antibodies. The principle of increasing the immunogenicity of antigens by engineering hybrids thereof may be applied not only for the treatment of polysensitized allergic patients but also for general vaccine development.
The only causative therapy approach for Type I allergy, allergen-specific immunotherapy, is based on the systemic administration of allergens to patients in order to induce allergen-specific "unresponsiveness" (6) . A major disadvantage of specific immunotherapy is that the allergen extracts used for vaccination are composed of mixtures of allergenic and nonallergenic components. Therapeutic allergen extracts may lack important allergens, the ratio of the individual components in the extract may greatly vary and it has been demonstrated that individual allergens exhibited different immunogenicity (6) (7) (8) . For the latter reasons, it is difficult to prepare vaccines for patients who are sensitized against several different allergen components (6) .
Because of their worldwide distribution and heavy pollen production, grasses represent one of the most important allergen sources for almost 400 million allergic patients (1, 9, 10) . Grass pollens contain several immunologically unrelated allergens against which allergic patients are frequently co-sensitized (11) . These allergens have been classified in different groups, of which group 1, group 2, group 5, and group 6 represent the most important allergens because they are recognized by the majority of grass pollen-allergic patients and induce strong clinical reactions (11) (12) (13) (14) (15) (16) .
Here we present an approach for the design of combination vaccines for the treatment of grass pollen-allergic patients with complex sensitization patterns. This approach is based on the generation of hybrid molecules of those grass pollen allergens against which the majority of grass pollen-allergic patients is co-sensitized. cDNAs coding for these allergens, fused by "gene soeing" (17) , are expressed as hybrid molecules in which each component acts as a molecular scaffold to increase the immunogenicity of the other component. Three hybrid molecules (rP2-P6, rP6-P2, rP5-P1), consisting of major timothy grass pollen allergens (Phl p 1, Phl p 2, Phl p 5, Phl p 6) that are representative for the major grass pollen allergen groups (11) (12) (13) (14) (15) , were engineered, expressed, and purified. Whether the relevant B cell and T cell epitopes are present in the hybrid molecules was demonstrated with specific antibody probes, by immunological competition experiments and lymphocyte proliferation experiments. Furthermore, mice were immunized to study the immunogenicity of the hybrid molecules and to analyze whether immunization induces IgG antibody responses, which can block the binding of grass pollenallergic patients' IgE antibodies to grass pollen allergens.
MATERIALS AND METHODS

Recombinant allergens, natural allergen extracts
Purified recombinant timothy grass pollen allergens Phl p 1 (26.1 kDa), Phl p 2 (10.7 kDa), Phl p 5 (28.5 kDa), and Phl p 6 (11.8 kDa), which had been expressed in E. coli (13) (14) (15) , were obtained from BIOMAY (Vienna, Austria). Pollen from Phleum pratense was purchased from Allergon Pharmacia (Välinge, Sweden). Aqueous pollen extracts were prepared and checked for quantity and quality of proteins by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue staining as described (18) (19) (20) . Total protein amounts were also measured by using a Micro BCA Protein Assay Reagent Kit (Pierce, Rockford, IL).
Characterization of allergic patients, allergen-specific rabbit antisera
Sera were obtained from 200 grass pollen-allergic patients. The diagnosis of grass pollen allergy was based on case history, skin-prick testing, and IgE serology (14). Total serum IgE levels and IgE levels specific for timothy grass pollen extract were determined by CAP RAST measurements (Pharmacia Diagnostics, Uppsala, Sweden). IgE reactivity profiles of the patients to natural and recombinant timothy grass pollen allergens were determined by Western blotting and ELISA, respectively (14).
Construction of plasmids expressing rP2-P6-, rP6-P2-, and rP5-P1 hybrid molecules cDNAs coding for hybrid molecules consisting of the major timothy grass pollen allergens Phl p 2 and Phl p 6 were constructed by using polymerase chain reaction (PCR)-based "gene soeing" (17) . To study whether the assembly of the allergens may affect the immunological properties of the resulting hybrid molecule, we constructed one hybrid, designated rP2-P6, containing Phl p 2 at the N-terminus and Phl p 6 at the C-terminus. The second hybrid molecule, rP6-P2, consisted of a N-terminal Phl p 6 and a C-terminal Phl p 2 unit. In a first PCR reaction, the cDNA coding for the complete rP6-P2 hybrid molecule was obtained by PCR using the primers P2a-5'and P2a-3' for Phl p 2 and P6a-5' and P6a-3' for Phl p 6 to create overlapping ends (Table 1) . In a subsequent PCR reaction the two gel-purified PCR products (QIAGEN gel purification kit, Quiagen, Hilden, Germany) were used as templates. The cDNA coding for the complete rP6-P2 hybrid molecule was obtained by PCR using the primers P2a-5' and P6a-3' (Table 1) . At the 3´ end of the Phl p 6 sequence, a hexahistidine tag was introduced followed by a stop codon and a BamHI restriction site. The resulting P2-P6 construct was inserted into the NdeI/BamHI site of plasmid pET17b (Novagen, Madison, WI).
The plasmid expressing a rP6-P2 hybrid molecule was constructed as described for the rP2-P6 hybrid molecule by using the primers P6b-5' and P6b-3' to amplify the cDNA coding for the Phl p 6 unit of the hybrid and the primers P2b-5' and P2b-3' to obtain a Phl p 2 encoding cDNA in the first PCR reaction ( Table 1) . The cDNA coding for the complete rP6-P2 hybrid molecule was obtained in a subsequent PCR reaction using the primers P6b-5' and P2b-3' (Table 1) . The resulting P6-P2 construct was inserted into the NdeI/BamHI site of the pET17b vector.
The rP5-P1 expressing plasmid was constructed by generating cDNAs coding for Phl p 5 and Phl p 1 by using the primers P5-5'/P5-3' and P1-5'/P1-3', respectively ( Table 1 ). The signal peptide of Phl p 5 was replaced by a NdeI restriction site containing the ATG start codon at the 5'end of the coding region. We introduced a KpnI restriction site into the 3'end of Phl p 5 by using a modified primer replacing the stop-codon. A cDNA coding for mature Phl p 1 containing a 5' KpnI restriction site and a nucleotide stretch coding for a C-terminal hexahistidine-tag followed by a BamHI site was obtained by PCR with appropriately modified primers. The two PCR products coding for Phl p 5 and Phl p 1 were united via the KpnI site and the resulting fragment cloned into the NdeI/BamHI site of the pET17b expression vector.
Expression in E. coli and purification of recombinant hybrid molecules
All constructs were transformed into E. coli BL21 (DE3) and expressed in liquid culture. Cells were grown in LB-medium containing 100 mg/l ampicillin to an OD 600 of 0.8. The expression of the recombinant proteins was induced by adding isopropyl-β-thiogalactopyranoside (IPTG) to a final concentration of 0.5mM. After 4 h at 37ûC, cells were harvested by centrifugation.
Recombinant P2-P6 and P6-P2 were expressed as soluble proteins. Cells were resuspended in lysis buffer (50 mM NaH 2 PO 4 ; 300 mM NaCl; 10 mM imidazole, pH 8.0) and lysed with an ultraturrax (Polytron, Kinematica, Bethlehem, PA). The lysate was centrifuged at 10,000 x g for 30 min at 4ûC to remove the cellular debris. The supernatant was loaded onto a Ni-NTA column (QIAGEN), which was washed, and the bound proteins were eluted with 250 mM imidazole and dialyzed against water.
Recombinant P5-P1 was expressed in the inclusion body fraction. Cells were resuspended in 10 mM Tris and 0.1% Triton, pH 7.4, and was lysed by adding lysozyme (QIAGEN). After centrifugation at 14,000 x g for 20 min at 4ûC, the pellet was washed 4 times with 5 mM Tris, pH 8.0; 0.05 M NaCl; 0.25% desoxicholate; 0.25 mM β-mercaptoethanol; and once with 10 mM Tris, pH 8.0, 3% isopropanole. Inclusion bodies were solubilized with 8 M urea; 100 mM NaH 2 PO 4 ; and 10 mM Tris, pH 8.0. After centrifugation at 14,000 x g for 20 min, the supernatant was loaded on a Ni-NTA column. The proteins were renatured on the column by using a linear 6-1 M urea gradient in 500 mM NaCl, 20% glycerol, and 20 mM Tris, pH 7.4, over a period of 1.5 h (21). Proteins were eluted by addition of 250 mM imidazole and were dialyzed against PBS, pH 7.4.
The purity and integrity of the proteins was checked by SDS-PAGE and Coomassie blue staining (19, 20) . Furthermore, nitrocellulose-blotted hybrid molecules were exposed to rabbit antisera, which had been raised against purified recombinant timothy grass pollen allergens (rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6) (14, 15) to demonstrate that the individual allergen components were exposed to antibodies.
Matrix-assisted laser desorption and ionization (MALDI)-time of flight (TOF) mass spectrometry and circular dichroism (CD) analysis of purified rP2-P6, rP6-P2, and rP5-P1
Laser desorption mass spectra were acquired in a linear mode with a TOF Compact MALDI II instrument (Kratos, Manchester, UK) (piCHEM, Graz, Austria). CD measurements were performed in MilliQ water with protein concentrations ranging from 0.11-0.17 mg/ml (2.0×10 6 -7.3×10 6 M). Protein mixes of the allergens were prepared by combining equimolar amounts of the single proteins to obtain a final protein concentration of 0.5 mg/ml, which was further diluted to a protein concentration of 0.17 mg/ml for the CD measurements. The investigations were performed on a Jasco (Tokyo, Japan) J-715 spectropolarimeter by using a 0.1 cm path-length cell equilibrated at 20ûC. Spectra were recorded with 0.5-nm resolution at a scan speed of 100 nm/min and were averaged from three scans. The final spectra were baseline-corrected by subtracting the corresponding buffer spectra obtained under identical conditions. Results were expressed as the mean residue ellipticity [Θ] at a given wavelength.
ELISA competition experiments
Sera from 20 representative grass pollen-allergic patients, diluted 1:5 in Tris-buffered saline (TBS), were preadsorbed overnight at 4ûC either with rPhl p 1, rPhl p 5, rP5-P1, rPhl p 2, rPhl p 6, rP2-P6, rP6-P2, BSA (10 µg/ml) or with timothy grass pollen extract (100 µg/ml). ELISA plates were coated with the individual recombinant allergens (rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6) (5 µg/ml) or timothy grass pollen extract (100 µg/ml) at 4ûC overnight. IgE binding of the pretreated sera to ELISA plate-coupled allergens was determined by duplicate determinations as described (14). The percentage inhibition of IgE binding to each of the allergens was calculated as follows: percentage of inhibition of IgE binding = 100 -(OD a /OD b ) × 100. OD a and OD b represent the optical density after preincubation with allergens and BSA, respectively.
T cell proliferation
Peripheral blood mononuclear cells (PBMC) were isolated from grass pollen-allergic patients containing Phl p 1-, Phl p 2-, Phl p 5-, and Phl p 6-specific IgE antibodies or from non-atopic persons mounting allergen-specific IgG antibodies by Ficoll (Biochrom, Berlin, Germany) density gradient centrifugation of heparinized venous blood samples. IgE and IgG subclass responses specific for recombinant timothy grass pollen allergens were determined by ELISA in the plasma samples of the allergic and non-atopic persons. Cells were resuspended in AIM V medium (Life Technologies, Grand Island, NY). Mononuclear cells (2×10 5 cells/well in 96-well plates) were stimulated with different Ag doses (50 µg/ml, 12.5 µg/ml, 3.125 µg/ml, 0.78 µg/ml) of rP2-P6, rP6-P2, rP5-P1, with equimolar mixtures of rPhl p 2/rPhl p 6, and rPhl p 1/rPhl p 5 or with medium alone in triplicates. The proliferative responses were measured after 6 days by [ 3 H]thymidine incorporation and are expressed as stimulation indices (22) .
Immunization of mice and measurement of specific antibody levels
Each of nine groups of eight female BALB/c mice (8 weeks old) (Charles River, Germany) were immunized subcutaneously with 2.5 µg rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6, 5µg rP2-P6, rP6-P2, rP5-P1, 100 µg timothy grass pollen extract, or an equimolar mixture of the four recombinant allergens adsorbed to Al(OH) 3 (Alu-Gel-S, Serva, Ingelheim, Germany) (8) . Animals were maintained in the animal care unit of the Dept. of Pathophysiology, University of Vienna, according to the local guidelines for animal care. Mice were immunized twice (day 1, day 28) and bled from the tail veins in 4-week intervals, and sera were stored at -20ûC until analysis.
IgG 1 responses against rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6, rP2-P6, rP6-P2, rP5-P1, and timothy grass pollen extract were measured by ELISA (8) . Allergens (recombinant allergens, 5 µg/ml; extract, 50 µg/ml) were coated to NUNC Maxisorp plates (Roskilde, Denmark) and were incubated with 1:1000 diluted mouse-sera. Bound IgG 1 antibodies were detected with a 1:1000 diluted monoclonal rat anti-mouse IgG 1 (Pharmingen, San Diego, CA,) and a 1:2000 diluted HRP-labeled sheep anti-rat antiserum (Amersham, Buckinghamshire, UK).
ELISA for assessment of blocking antibody activity
The ability of the mouse anti-rP2-P6, anti-rP6-P2, and anti-rP5-P1 antibodies to inhibit the binding of grass pollen-allergic patients' IgE antibodies to rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6, or timothy grass pollen extract was examined by ELISA competition experiments as described (8, 23) . Recombinant Phl p 1, Phl p 2, Phl p 5, Phl p 6 (1 µg/ml), or timothy grass pollen extract (100 µg/ml) were coated to ELISA plates (NUNC) and were preincubated with mouse anti-rP2-P6, anti-rP6-P2, and anti-rP5-P1 antisera or, for control purposes, with the corresponding preimmune sera each diluted 1:50. Blocking of allergic patients IgE binding to plate-coupled timothy grass pollen extract (100 µg/ml) was shown with sera from timothy grass pollen extractimmunized mice or a 1:1 mix of mouse anti-rP5-P1 and anti-rP6-P2 antisera each diluted 1:50. After washing, plates were incubated with 1:5 diluted human sera from grass pollen-allergic patients and bound human IgE was detected with an AP-labeled mouse monoclonal anti-human IgE Ab (Pharmingen). The percentage reduction of human IgE binding after preincubation with mouse antisera was determined according to the formula: percentage of inhibition of IgE binding = 100-OD I /OD P × 100. OD I and OD P represent the extinctions after preincubation with the immune serum and the preimmune serum, respectively.
RESULTS
Genetic engineering and purification of recombinant hybrid molecules consisting of immunologically unrelated grass pollen allergens
Recombinant Phl p 1, Phl p 2, Phl p 5, and Phl p 6 represent the most important grass pollen allergens, which contain the majority of the epitopes present in natural grass pollen extracts (11) (12) (13) (14) (15) (16) . According to the rates of co-sensitization determined in a population of 200 grass pollenallergic patients (rPhl p 1+rPhl p 5: 60%; rPhl p 2+rPhl p 6: 30%), we engineered hybrid molecules consisting of immunologically unrelated allergen components by PCR-based "genesoeing". With this method, cDNAs coding for a hybrid consisting of Phl p 2 (N-terminus) and Phl p 6 (C-terminus) (i.e., rP2-P6), one hybrid consisting of Phl p 6 (N-terminus) and Phl p 2 (Cterminus) (i.e., rP6-P2) and a hybrid made of Phl p 5 (N-terminus) and Phl p 1 (C-terminus) (i.e., rP5-P1), were inserted into expression plasmids. The hybrid molecules were expressed at high levels in E. coli (10-15 mg/l culture) and were purified to homogeneity by Nickel affinity chromatography. The rP2-P6 and rP6-P2 hybrids were expressed in the soluble cytoplasmic fraction of E. coli. The rP5-P1 hybrid formed inclusion bodies from which the protein could be isolated by using a denaturation step and a subsequent refolding protocol. Figure 1 shows a Coomassie-stained SDS-PAGE comparing the purified hybrid molecules with the individual recombinant timothy grass pollen allergens rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6. Although the rP2-P6 and rP6-P2 hybrid exhibited a slightly different migration pattern in SDS-PAGE (Fig.  1) , mass spectroscopical analysis revealed an almost identical molecular mass (rP2-P6: 23935 Da; rP6-P2: 23910 Da), which was in agreement with the molecular weight calculated according to the deduced amino acid sequences of the proteins. Likewise, the molecular mass determined by mass spectroscopy for the rP5-P1 hybrid molecule (55972 Da) was in agreement with the molecular weight predicted for the protein.
Recombinant hybrid molecules contain a considerable amount of secondary structure
The CD spectrum of the equimolar mix of rPhl p 2 and rPhl p 6 indicates a mixed α-and ß-secondary structure with a minimum at around 207 nm and a broad shoulder between 215 and 225 nm, which is in agreement with the fact that rPhl p 2 represents a protein with almost exclusive ß-sheet structure (24) , and rPhl p 6 is an almost exclusive α-helical protein (15) . The rP2-P6 hybrid exhibits a spectrum comparable with that of the rPhl p 2/rPhl p 6 protein mix, with a slightly smaller minimum at 207 nm ( Fig. 2A) . The shape of the curve recorded for the rP6-P2 hybrid is almost superimposable to the curve of the mix and that of the rP2-P6 hybrid, but the signal increased by about 25% (Fig. 2A) .
The CD spectrum recorded for the rPhl p 1/rPhl p 5 mix is dominated by minima at 208 nm and 222 nm typical for α-helices but also contains ß-sheet secondary structures (Fig. 2B) . The zerocrossing was shifted significantly below 200 nm, indicating that an increasing portion of the proteins are in random coil conformation. Because rPhl p 5 represents an almost exclusive α-helical protein (25) , it is likely that the presence of ß-sheet elements and the shift are due to largely unfolded rPhl p 1. This assumption is supported by our finding that rPhl p 1 by itself is mainly unfolded (Ball, T., and Valenta, R., unpublished observations). The rP5-P1 hybrid exhibits a CD spectrum similar to the rPhl p 1/rPhl p 5 protein mix but with a reduced fold (Fig.  2B) .
Hybrid molecules present the B cell epitopes of the individual allergen components
To test whether the hybrid molecules present the B cell epitopes of the individual components, we performed two types of experiments. First, we used rabbit-antisera raised against the individual recombinant allergens (rabbit anti-Phl p 1, anti-Phl p 2, anti-Phl p 5, and anti-Phl p 6 antibodies) to demonstrate binding to the hybrid molecules (data not shown). Second, we used immunological competition experiments to investigate whether the hybrid allergens can block the binding of grass pollen-allergic patients' (n=20) IgE antibodies to the individual allergen components ( Table 2) . We found that the rP2-P6, as well as the rP6-P2 hybrid, inhibited IgE binding to each of the components (rPhl p 2, rPhl p 6) equally well as the single recombinant allergens. Similar results were obtained for the rP5-P1 hybrid, which inhibited IgE binding of all 20 sera to rPhl p 1 and rPhl p 5, as efficient as the single components (Table 2) . By using an equimolar mixture of the rP5-P1 and rP6-P2 hybrid molecules, we found that most of the timothy grass pollen extract-specific IgE could be adsorbed from sera of the 20 grass pollen-allergic patients ( Table 3 ). The average inhibition of IgE binding to timothy grass pollen extract obtained with the two hybrid molecules was 64% and thus almost comparable with that achieved with timothy grass pollen extract (average inhibition 81%) ( Table 3) . That no epitopes were hidden in the hybrid molecules is remarkable considering that the hybrids contained only an intermolecular weight spacer of two amino acids.
Hybrid molecules resemble the T cell epitopes of the individual allergen components
To investigate whether the hybrid molecules rP2-P6, rP6-P2, and rP5-P1 contain the T cell epitopes of the individual allergen components, we performed in vitro proliferation experiments with PBMC from four grass pollen-allergic patients. As shown for one representative out of four grass pollen-allergic patients, we found that the hybrid allergens as well as equimolar mixtures of the individual allergens induced proliferation of PBMC (Fig. 3A) . The rP5-P1 hybrid containing the two most important timothy grass pollen allergens (Phl p 1, Phl p 5) induced at all doses a stronger lymphoproliferative response than the mix of rPhl p 5 and rPhl p 1, which was even stronger than that induced by natural timothy grass pollen extract ( Fig. 3A; data not shown). The rPhl p 2/rPhl p 6 protein mix induced significant proliferative responses only at high concentrations (≥12.5 µg/ml) in the allergic patients. Again a much higher proliferative response was obtained with the hybrid molecules (rP2-P6; rP6-P2) at the highest concentration (50 µg/ml) (Fig. 3A) . Using PBMC from non-allergic individuals who contained allergen-specific IgG antibodies but no specific IgE, proliferative responses could be induced by the hybrid molecules and, to a lower extent, by the individual allergen components (Fig. 3B) . The latter finding is in agreement with previous studies demonstrating allergen-specific lymphoproliferative responses in non-atopic persons (26-28).
Immunization with recombinant hybrid molecules induces stronger and earlier IgG responses than immunization with individual allergens or allergen extract
To evaluate whether immunization with the hybrid allergens induces IgG antibodies that recognize the individual allergen components, groups of eight mice each were immunized with the hybrids, the individual allergens, or timothy grass pollen extract. Figure 4 demonstrates that the average IgG 1 responses induced by the hybrid molecules to each of the individual allergens (rPhl p 1, rPhl p 2, rPhl p 5, or rPhl p 6) were higher than those obtained by immunization with the single-allergen components. IgG 1 antibody levels induced by the hybrids were already detectable 4 weeks after the first immunization and had increased further after 4 more weeks. Perhaps most interesting was the finding that the hybrid molecules induced higher IgG 1 levels to the individual allergen components than did timothy grass pollen extract or an equimolar mix of the four recombinant allergens (Fig. 4) . The latter was particularly evident for Phl p 2, as well as for Phl p 6 and also for Phl p 1, which were poorly recognized by extract-immunized mice; whereas the hybrid molecules induced vigorous anti-Phl p 1-, anti-Phl p 2-, and anti-Phl p 6 antibody responses (Fig. 4) . The higher induction of IgG anti-Phl p 5 and anti-Phl p 6 responses by allergen extract and the allergen mix compared with immunization with the isolated allergen may be explained by partial cross-reactivity between Phl p 5 and Phl p 6 (15) .
Hybrid molecules induce antibodies that block the binding of allergic patients´ IgE to grass pollen allergens
Next we examined whether mouse antibodies induced with the hybrid molecules can block the binding of grass pollen-allergic patients' IgE antibodies to purified grass pollen allergens (Table  4) . ELISA competition experiments performed with sera from four representative grass pollenallergic patients showed that antibodies induced by the hybrid molecules strongly inhibited IgE binding to the purified allergens. IgG antibodies induced with the rP2-P6 and the rP6-P2 hybrid molecule caused a 48-54% inhibition of IgE binding to Phl p 2 and a 54-67% inhibition of IgE binding to Phl p 6 (Table 4A) . By contrast, the inhibition of IgE reactivity yielded by preincubation with antibodies induced with rPhl p 2 and rPhl p 6 alone was very low (0-15%) (Table 4A ). Anti-P5-P1 antibodies caused a more than double inhibition of IgE binding to Phl p 5 (60% average inhibition) than antibodies raised against Phl p 5 alone (28%) ( Table 4B ). The inhibition of IgE binding to Phl p 1 yielded with the antibodies raised against the rP5-P1 hybrid (19% average inhibition) and Phl p 1 alone (30% average inhibition) were lower (Table 4B) . Perhaps most important was the fact that mouse antibodies raised against the rP5-P1 and rP6-P2 hybrid inhibited allergic patients IgE binding to timothy grass pollen extract even stronger than extract-induced antibodies (average inhibition hybrids: 66%; average inhibition extract: 63%) (Table 4C) .
DISCUSSION
Grass pollen allergy affects more than 400 million allergic patients worldwide. Specific immunotherapy, the only causal therapy approach for grass pollen allergy, uses allergen extracts prepared from grass pollen. As exemplified in Figure 5 , grass pollen allergen extracts consist of a variety of different allergens and non-allergenic components (6, 29, 30) . Although it is possible to quantify the amount of certain allergens in therapeutic allergen extract preparations, it is not possible to influence the concentrations of the individual allergens in the vaccine preparation or to deplete non-allergenic components (31) . Moreover, it has been demonstrated that different grass pollen allergens exhibit different immunogenicity (Phl p 5>Phl p 1>Phl p 6>Phl p 2) in animals (8); accordingly it has been observed that immunotherapy based on grass pollen allergen extracts induces highly heterogenous immune responses (32-36; Valenta, R. and Mothes, N., unpublished observations) (Fig. 5a ). In this context it has been reported that extract-based immunotherapy can even induce IgE antibodies towards new allergens (32, 35, 37) and lead to clinically relevant new sensitizations (38) . By using recombinant allergen molecules for diagnosis and treatment, it is-in principle-possible to tailor treatment according to the patient's sensitization profile and thus avoid the induction of irrelevant or even unwanted immune responses (29, 39) . Treatment of allergy to complex allergen sources may, however, still be hampered by the different immunogenicity of the individual allergen molecules, which may give rise to heterogenous immune responses even when these allergens are administered in equimolar mixtures (30, 32) (Fig. 5b) .
Here we report the development of combination vaccines based on recombinant hybrid molecules consisting of four of the most important and frequently recognized grass pollen allergens (i.e., Phl p 1, Phl p 2, Phl p 5, Phl p 6) (40) (41) (42) 15) . These combination vaccines have been developed based on the most frequent co-sensitization patterns of grass pollen-allergic patients and thus should be suited for patient-tailored treatment of the majority of grass pollenallergic patients.
An unexpected finding of great importance for immunotherapy as well as vaccination in general was the strong increase of immunogenicity of unrelated allergens with poor immunogenicity (e.g., Phl p 2, Phl p 6) that was obtained by their production as hybrid molecules (Fig. 5C ). Hybrid molecules consisting of immunologically unrelated allergens, (i.e., Phl p 2 and Phl p 6, as well as of Phl p 1 and Phl p 5), induced earlier and higher IgG antibody responses in mice and more vigorous lymphoproliferative responses in cultured mononuclear cells obtained from sensitized patients and individuals containing allergen-specific IgG antibodies than the individual allergens or equimolar mixtures thereof.
Several mutually nonexclusive explanations may be considered for this observation. First, it may be assumed that within the hybrid molecule each of the allergens can act as carrier molecule and thus enhance humoral as well as cellular immune responses to the linked component (43) (44) (45) (46) (47) (48) . The enhancement of immune responses in the case of the rP5-P1 hybrid molecule may be understood according to the principle of classical carrier effects. In this scenario, covalent linkage of a less immunogenic allergen (i.e., Phl p 1) with a highly immunogenic allergen (i.e., Phl p 5) containing a variety of potent T cell epitopes would explain the enhanced immunogenicity to the first allergen when it is presented in the context of the latter. However, we found that fusion of two different allergens with low capacity to induce antibody or lymphoproliferative responses (i.e., Phl p 2, Phl p 6) led to an almost equal enhancement of immune responses to each of the components. The increased immunogenicity observed for the rP2-P6 and the rP6-P2 hybrid molecules cannot be explained exclusively by the carrier effect alone because these hybrids did not contain additional potent T cell epitopes. It seems also unlikely that potent T cell epitopes or a molecular environment favoring vigorous T cell responses were created de novo (49) in these hybrid molecules because they did not contain relevant new sequences, and the order of the allergens had no apparent influence on the enhancement of immunogenicity.
Because our antigen preparations represented pure proteins, we consider T cell-independent carrier effects as were described for monophosphoryl lipid A (MLA) as a second, rather unlikely possibility for their increased immunogenicity (50) .
Whether the hybrid molecules induce a different repertoire of co-stimulatory molecules on immune cells or are processed in a different manner compared with the isolated allergens remains to be elucidated (51, 52) . However, the analysis of the secondary structure of the hybrid molecules and the equimolar allergen mixes by circular dichroism demonstrates similar folds. It therefore appears unlikely that changes in secondary structure or fold may have caused profound differences in the presentation of the hybrid molecules versus the isolated allergens.
Although we cannot provide a definitive answer for the mechanisms that are operative in the enhancement of immunogenicity of the hybrid molecules, we suggest fusion of lowimmunogenic vaccine components against which protective immune responses are required as a generally applicable principle for immunotherapy and general vaccination. The principle of linking relevant antigens (e.g., allergens) by recombinant DNA technology may be applied whenever it is desired to induce strong protective immune responses or alternatively tolerization against independent and immunologically unrelated antigens (48, 53, 54) without using a foreign carrier molecule, which may give rise to unwanted immune responses. Another advantage of recombinant hybrid molecules is that they can be produced as defined molecular entities by standardized procedures, avoiding complicated chemical coupling and purification procedures. Our assumption, that the suggested strategy can be applied as a general principle, is supported by the finding that the immunogenicity of four different antigens could be increased by the hybrid approach.
The hybrids described in our study appear suitable for specific immunotherapy of grass pollen allergy because they contain most of the IgE epitopes and T cell epitopes present in natural grass pollen extract (14, 15, 55) . Second, immunization of mice with the hybrid molecules induced strong and early induction of allergen-specific IgG antibody responses, which strongly blocked the binding of grass pollen-allergic patients' IgE antibodies to the individual allergens, as well as to grass pollen extract (Table 4) . Moreover, we found that the hybrid molecules induced stronger lymphoproliferative responses in human allergen-specific mononuclear cells than the isolated allergen components.
The basic mechanisms underlying allergen-specific immunotherapy are not fully understood (56) , and there is still considerable controversy regarding the importance of T cell and B cell epitopes for successful immunotherapy (57) (58) (59) . Therefore, we have presently constructed hybrids consisting of allergen molecules, which closely resemble the immunological properties of natural grass pollen allergens. To reduce therapy-induced side effects resulting from the administration of active allergens, it will in principle be possible to construct hybrid molecules consisting of hypoallergenic allergen derivatives (57) .
We suggest vaccination with recombinant hybrid molecules as a generally applicable strategy whenever the induction of simultaneous immune responses against unrelated antigens with different immunogenicity is desired. rPhl p 1 and rPhl p 5; C: timothy grass pollen extract) were preincubated with mouse antisera (mouse anti-rP2-P6, antirP6-P2, anti-rPhl p 2, anti-rPhl p 6, anti-rP5-P1, anti-rPhl p 1, anti-rPhl p 5, or a mix of anti-rP6-P2 and anti-rP5-P1 antisera). The percentages inhibition of IgE binding obtained for four grass pollen-allergic patients (1-4) are displayed. 
